266
Participants
Start Date
June 30, 2005
Primary Completion Date
May 31, 2007
Study Completion Date
January 31, 2016
TDF
300 mg tablet administered orally once daily
ADV
10 mg tablet administered orally once daily
TDF placebo
Tablet administered orally once daily
ADV placebo
Tablet administered orally once daily
FTC/TDF
200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Sofia
Sofia
Camperdown
Concord
Westmead
Prahran
Footscray
Rotterdam
Parkville
Fitzroy
Clayton
Woolloongabba
Perth
Varna
New York
New York
New York
Berlin
Flushing
Athens
Hamburg
Baltimore
Fairfax
Falls Church
Richmond
Kiel
Atlanta
Atlanta
Hanover
Miami
Grenoble
Bologna
Düsseldorf
Düsseldorf
Herne
Essen
Valencia
Ann Arbor
Detroit
Nancy
Thessaloniki
Mainz
Thessaloniki
Lille
Brno
St Louis
Homburg/Saar
Strasbourg
Lyon
Tübingen
Paris
München
Pasadena
San Diego
Clichy
Orange
San Jose
Honolulu
Seattle
Calgary
Vancouver
Winnepeg
Toronto
Toronto
Hradec Králové
Auckland
Hamilton
Wellington
Whakatane
Bursa
Istanbul
Izmir
Prague
Praha 6- Stresovice
Bialystok
Bydgoszcz
Chorzów
Kielce
Krakow
Warsaw
Wroclaw
Barcelona
Barcelona
Barcelona
Ankara
Birmingham
London
Lead Sponsor
Gilead Sciences
INDUSTRY